Bristol-Myers Squibb's $14 billion bet on buying Karuna Therapeutics looks set to pay off after it got FDA approval for the schizophrenia drug at the heart of the deal.
AstraZeneca's EGFR inhibitor Tagrisso has been approved by the FDA for a new lung cancer indication that could make it a go-to therapy for a patient population that until now had no targete
In the space of four days, the number of FDA-approved therapies for ultra-rare genetic disorder Niemann-Pick disease has gone from zero to two, transforming the prospects for patients.
Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme.
Aurion Biotech has launched its cell therapy Vyznova for serious eye disorder bullous keratopathy in Japan, its debut market, becoming an alternative to corneal replacement using donor tiss
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
